A novel serum metabolomic panel distinguishes IgG4-related sclerosing cholangitis from primary sclerosing cholangitis

<p><strong>Background &amp; Aims:&nbsp;</strong>Primary sclerosing cholangitis (PSC) and IgG4-related sclerosing cholangitis (IgG4-SC) are chronic fibro-inflammatory immune-mediated hepatobiliary conditions that are challenging to distinguish in a clinical setting. Accurate...

وصف كامل

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Radford-Smith, DE, Selvaraj, EA, Peters, R, Orrell, M, Bolon, J, Anthony, DC, Pavlides, M, Lynch, K, Geremia, A, Bailey, A, Culver, EL, Probert, F
التنسيق: Journal article
اللغة:English
منشور في: Wiley 2022
_version_ 1826309558729965568
author Radford-Smith, DE
Selvaraj, EA
Peters, R
Orrell, M
Bolon, J
Anthony, DC
Pavlides, M
Lynch, K
Geremia, A
Bailey, A
Culver, EL
Probert, F
author_facet Radford-Smith, DE
Selvaraj, EA
Peters, R
Orrell, M
Bolon, J
Anthony, DC
Pavlides, M
Lynch, K
Geremia, A
Bailey, A
Culver, EL
Probert, F
author_sort Radford-Smith, DE
collection OXFORD
description <p><strong>Background &amp; Aims:&nbsp;</strong>Primary sclerosing cholangitis (PSC) and IgG4-related sclerosing cholangitis (IgG4-SC) are chronic fibro-inflammatory immune-mediated hepatobiliary conditions that are challenging to distinguish in a clinical setting. Accurate non-invasive biomarkers for discriminating PSC and IgG4-SC are important to ensure a correct diagnosis, prompt therapy and adequate cancer surveillance.</p> <p><strong>Methods:&nbsp;</strong>We performed nuclear magnetic resonance (NMR)-based metabolomic profiling using serum samples collected prospectively from patients with PSC (<em>n</em>&nbsp;=&nbsp;100), IgG4-SC (<em>n</em>&nbsp;=&nbsp;23) and healthy controls (HC;&nbsp;<em>n</em>&nbsp;=&nbsp;16).</p> <p><strong>Results:&nbsp;</strong>Multivariate analysis of the serum metabolome discriminated PSC from IgG4-SC with greater accuracy (AUC 0.95 [95%CI 0.90&ndash;0.98]) than IgG4 titre (AUC 0.87 [95%CI 0.79&ndash;0.94]). When inflammatory bowel disease (IBD) was excluded as a comorbid condition (IgG4-SC&nbsp;<em>n</em>&nbsp;=&nbsp;20, PSC&nbsp;<em>n</em>&nbsp;=&nbsp;22), the diagnostic AUC increased to 1.0, suggesting that the metabolome differences identified are not a result of the increased prevalence of IBD in PSC relative to IgG4-SC patients. Serum lactate (<em>p</em>&nbsp;&lt;&nbsp;.0001), glucose (<em>p</em>&nbsp;&lt;&nbsp;.01) and glutamine (<em>p</em>&nbsp;&lt;&nbsp;.01) metabolites were increased in IgG4-related disease (IgG4-RD) and IgG4-SC individuals compared to PSC, whereas mobile choline (<em>p</em>&nbsp;&lt;&nbsp;.05), 3-hydroxybutyric acid (<em>p</em>&nbsp;&lt;&nbsp;.01) and -CH<sub>3</sub>&nbsp;lipoprotein resonances (<em>p</em>&nbsp;&lt;&nbsp;.01) were decreased.</p> <p><strong>Conclusions:&nbsp;</strong>Taken together, serum metabolomic profiling has the potential to be incorporated as a diagnostic criterion, independent of IgG4 titre, to improve the diagnosis of IgG4-RD and help distinguish IgG4-SC from PSC.</p>
first_indexed 2024-03-07T07:37:33Z
format Journal article
id oxford-uuid:272363cf-8200-44a2-9bb7-87faa4c7b29c
institution University of Oxford
language English
last_indexed 2024-03-07T07:37:33Z
publishDate 2022
publisher Wiley
record_format dspace
spelling oxford-uuid:272363cf-8200-44a2-9bb7-87faa4c7b29c2023-03-31T06:38:52ZA novel serum metabolomic panel distinguishes IgG4-related sclerosing cholangitis from primary sclerosing cholangitisJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:272363cf-8200-44a2-9bb7-87faa4c7b29cEnglishSymplectic ElementsWiley2022Radford-Smith, DESelvaraj, EAPeters, ROrrell, MBolon, JAnthony, DCPavlides, MLynch, KGeremia, ABailey, ACulver, ELProbert, F<p><strong>Background &amp; Aims:&nbsp;</strong>Primary sclerosing cholangitis (PSC) and IgG4-related sclerosing cholangitis (IgG4-SC) are chronic fibro-inflammatory immune-mediated hepatobiliary conditions that are challenging to distinguish in a clinical setting. Accurate non-invasive biomarkers for discriminating PSC and IgG4-SC are important to ensure a correct diagnosis, prompt therapy and adequate cancer surveillance.</p> <p><strong>Methods:&nbsp;</strong>We performed nuclear magnetic resonance (NMR)-based metabolomic profiling using serum samples collected prospectively from patients with PSC (<em>n</em>&nbsp;=&nbsp;100), IgG4-SC (<em>n</em>&nbsp;=&nbsp;23) and healthy controls (HC;&nbsp;<em>n</em>&nbsp;=&nbsp;16).</p> <p><strong>Results:&nbsp;</strong>Multivariate analysis of the serum metabolome discriminated PSC from IgG4-SC with greater accuracy (AUC 0.95 [95%CI 0.90&ndash;0.98]) than IgG4 titre (AUC 0.87 [95%CI 0.79&ndash;0.94]). When inflammatory bowel disease (IBD) was excluded as a comorbid condition (IgG4-SC&nbsp;<em>n</em>&nbsp;=&nbsp;20, PSC&nbsp;<em>n</em>&nbsp;=&nbsp;22), the diagnostic AUC increased to 1.0, suggesting that the metabolome differences identified are not a result of the increased prevalence of IBD in PSC relative to IgG4-SC patients. Serum lactate (<em>p</em>&nbsp;&lt;&nbsp;.0001), glucose (<em>p</em>&nbsp;&lt;&nbsp;.01) and glutamine (<em>p</em>&nbsp;&lt;&nbsp;.01) metabolites were increased in IgG4-related disease (IgG4-RD) and IgG4-SC individuals compared to PSC, whereas mobile choline (<em>p</em>&nbsp;&lt;&nbsp;.05), 3-hydroxybutyric acid (<em>p</em>&nbsp;&lt;&nbsp;.01) and -CH<sub>3</sub>&nbsp;lipoprotein resonances (<em>p</em>&nbsp;&lt;&nbsp;.01) were decreased.</p> <p><strong>Conclusions:&nbsp;</strong>Taken together, serum metabolomic profiling has the potential to be incorporated as a diagnostic criterion, independent of IgG4 titre, to improve the diagnosis of IgG4-RD and help distinguish IgG4-SC from PSC.</p>
spellingShingle Radford-Smith, DE
Selvaraj, EA
Peters, R
Orrell, M
Bolon, J
Anthony, DC
Pavlides, M
Lynch, K
Geremia, A
Bailey, A
Culver, EL
Probert, F
A novel serum metabolomic panel distinguishes IgG4-related sclerosing cholangitis from primary sclerosing cholangitis
title A novel serum metabolomic panel distinguishes IgG4-related sclerosing cholangitis from primary sclerosing cholangitis
title_full A novel serum metabolomic panel distinguishes IgG4-related sclerosing cholangitis from primary sclerosing cholangitis
title_fullStr A novel serum metabolomic panel distinguishes IgG4-related sclerosing cholangitis from primary sclerosing cholangitis
title_full_unstemmed A novel serum metabolomic panel distinguishes IgG4-related sclerosing cholangitis from primary sclerosing cholangitis
title_short A novel serum metabolomic panel distinguishes IgG4-related sclerosing cholangitis from primary sclerosing cholangitis
title_sort novel serum metabolomic panel distinguishes igg4 related sclerosing cholangitis from primary sclerosing cholangitis
work_keys_str_mv AT radfordsmithde anovelserummetabolomicpaneldistinguishesigg4relatedsclerosingcholangitisfromprimarysclerosingcholangitis
AT selvarajea anovelserummetabolomicpaneldistinguishesigg4relatedsclerosingcholangitisfromprimarysclerosingcholangitis
AT petersr anovelserummetabolomicpaneldistinguishesigg4relatedsclerosingcholangitisfromprimarysclerosingcholangitis
AT orrellm anovelserummetabolomicpaneldistinguishesigg4relatedsclerosingcholangitisfromprimarysclerosingcholangitis
AT bolonj anovelserummetabolomicpaneldistinguishesigg4relatedsclerosingcholangitisfromprimarysclerosingcholangitis
AT anthonydc anovelserummetabolomicpaneldistinguishesigg4relatedsclerosingcholangitisfromprimarysclerosingcholangitis
AT pavlidesm anovelserummetabolomicpaneldistinguishesigg4relatedsclerosingcholangitisfromprimarysclerosingcholangitis
AT lynchk anovelserummetabolomicpaneldistinguishesigg4relatedsclerosingcholangitisfromprimarysclerosingcholangitis
AT geremiaa anovelserummetabolomicpaneldistinguishesigg4relatedsclerosingcholangitisfromprimarysclerosingcholangitis
AT baileya anovelserummetabolomicpaneldistinguishesigg4relatedsclerosingcholangitisfromprimarysclerosingcholangitis
AT culverel anovelserummetabolomicpaneldistinguishesigg4relatedsclerosingcholangitisfromprimarysclerosingcholangitis
AT probertf anovelserummetabolomicpaneldistinguishesigg4relatedsclerosingcholangitisfromprimarysclerosingcholangitis
AT radfordsmithde novelserummetabolomicpaneldistinguishesigg4relatedsclerosingcholangitisfromprimarysclerosingcholangitis
AT selvarajea novelserummetabolomicpaneldistinguishesigg4relatedsclerosingcholangitisfromprimarysclerosingcholangitis
AT petersr novelserummetabolomicpaneldistinguishesigg4relatedsclerosingcholangitisfromprimarysclerosingcholangitis
AT orrellm novelserummetabolomicpaneldistinguishesigg4relatedsclerosingcholangitisfromprimarysclerosingcholangitis
AT bolonj novelserummetabolomicpaneldistinguishesigg4relatedsclerosingcholangitisfromprimarysclerosingcholangitis
AT anthonydc novelserummetabolomicpaneldistinguishesigg4relatedsclerosingcholangitisfromprimarysclerosingcholangitis
AT pavlidesm novelserummetabolomicpaneldistinguishesigg4relatedsclerosingcholangitisfromprimarysclerosingcholangitis
AT lynchk novelserummetabolomicpaneldistinguishesigg4relatedsclerosingcholangitisfromprimarysclerosingcholangitis
AT geremiaa novelserummetabolomicpaneldistinguishesigg4relatedsclerosingcholangitisfromprimarysclerosingcholangitis
AT baileya novelserummetabolomicpaneldistinguishesigg4relatedsclerosingcholangitisfromprimarysclerosingcholangitis
AT culverel novelserummetabolomicpaneldistinguishesigg4relatedsclerosingcholangitisfromprimarysclerosingcholangitis
AT probertf novelserummetabolomicpaneldistinguishesigg4relatedsclerosingcholangitisfromprimarysclerosingcholangitis